ReviewCell transplantation
Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement.
Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Off‑the‑shelf, engineered non-living stem cell strategy for advancing cellular therapies.Nature biomedical engineering · 2026Article
- Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy.iScience · 2026Review
- Intramuscular administration of mesenchymal stromal cells in a cat with asthma: case report.Journal of veterinary internal medicine · 2026Article
- Inhalable stem cell-derived artificial nanovesicles for targeted siRNA delivery to effectively alleviate asthma symptoms.Asian journal of pharmaceutical sciences · 2026Article
- Clinical Remission in Severe Asthma: A Comparative Analysis of Patients with and Without Biologics from the Swiss Severe Asthma Registry.Biomedicines · 2025Article
- Single-cell transcriptomic analysis of the heterogeneity of mesenchymal and stromal cells and their regulon alteration during airway remodeling in asthma.Scientific reports · 2025Article
- Exploring the critical therapeutic window: Dose-frequency optimization of human umbilical cord mesenchymal stem cells for preclinical asthma treatment.World journal of stem cells · 2025Article
- Article
- Asthma and stem cell therapy.World journal of stem cells · 2025Review
- Migrasomes derived from human umbilical cord mesenchymal stem cells: a new therapeutic agent for ovalbumin-induced asthma in mice.Stem cell research & therapy · 2025Article
- Comparison of efficacy of exosomes derived from human umbilical cord blood mesenchymal stem cells in treating mouse acute lung injury via different routes.Frontiers in pediatrics · 2025Article
- Mitochondrial Dysfunction and Metabolic Reprogramming in Obesity and Asthma.International journal of molecular sciences · 2024Review
- Unlocking the code for stroke treatment and care.Journal of central nervous system disease · 2024Article
- Immortalized Canine Adipose-Derived Mesenchymal Stem Cells Maintain the Immunomodulatory Capacity of the Original Primary Cells.International journal of molecular sciences · 2023Article
- Therapeutic Effects of Mesenchymal Stromal Cells Require Mitochondrial Transfer and Quality Control.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a complex and heterogeneous disease characterized by chronic airway inflammation, airway hyperresponsiveness, and airway remodeling. Most asthmatic patients are well-established using standard treatment strategies and advanced biologicals. However, a small group of patients who do not respond to biological treatments or are not effectively controlled by available treatment strategies remain a clinical challenge. Therefore, new therapies are urgently needed for poorly controlled asthma. Mesenchymal stem/stromal cells (MSCs) have shown therapeutic potential in relieving airway inflammation and repairing impaired immune balance in preclinical trials owing to their immunomodulatory abilities. Noteworthy, MSCs exerted a therapeutic effect on steroid-resistant asthma with rare side effects in asthmatic models. Nevertheless, adverse factors such as limited obtained number, nutrient and oxygen deprivation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.